| User's Publication |
|
22145
Chow T, Humble W, Lucarelli E, Onofrillo C, Choong PF, Di Bella C, Duchi S.
Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.
iScience
2024
27(9):110251
PubMed ID: 39286504
DOI: 10.1016/j.isci.2024.110251
|
|
17357
Hayashi T, Yamamoto N, Kurosawa G, Tajima K, Kondo M, Hiramatsu N, Kato Y, Tanaka M, Yamaguchi H, Kurosawa Y, Yamada H, Fujita N.
A Novel High-Throughput Screening Method for a Human Multicentric Osteosarcoma-Specific Antibody and Biomarker Using a Phage Display-Derived Monoclonal Antibody
Cancers (Basel)
2022
14(23):5829
PubMed ID: 36497311
DOI: 10.3390/cancers14235829
|
|
13409
Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T.
Direct conversion of osteosarcoma to adipocytes by targeting TNIK.
JCI Insight
2021
PubMed ID: 33400690
DOI: 10.1172/jci.insight.137245
|
|
20022
Rathore R, Caldwell KE, Schutt C, Brashears CB, Prudner BC, Ehrhardt WR, Leung CH, Lin H, Daw NC, Beird HC, Giles A, Wang WL, Lazar AJ, Chrisinger JSA, Livingston JA, Van Tine BA.
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma.
Cell Rep
2021
34(4):108678
PubMed ID: 33503424
DOI: 10.1016/j.celrep.2020.108678
|
|
13253
Fujiwara S, Kawamoto T, Kawakami Y, Koterazawa Y, Hara H, Takemori T, Kitayama K, Yahiro S, Kakutani K, Matsumoto T, Matsushita T, Niikura T, Koyanagi-Aoi M, Aoi T, Kuroda R, Akisue T.
Acquisition of cancer stem cell properties in osteosarcoma cells by defined factors.
Stem Cell Res Ther
2020
PubMed ID: 33008481
DOI: 10.1186/s13287-020-01944-9
|
|
19258
Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T.
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma
Mol Cancer Ther
2019
9(3):535-44
PubMed ID: 20159990
DOI: 10.1158/1535-7163.MCT-09-0774
|
|
7043
Ando T, Kudo Y, Iizuka S, Tsunematsu T, Umehara H, Shrestha M, Matsuo T, Kubo T, Shimose S, Arihiro K, Ogawa I, Ochi M, Takata T.
Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma.
Sci Rep
2017
7:40187
PubMed ID: 28054649
DOI: 10.1038/srep40187
|
|
10039
Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T, Komiya S.
Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
Oncol. Rep.
2017
37:1141-1147
PubMed ID: 27959425
DOI: 10.3892/or.2016.5310
|
|
7459
Tsuru A, Setoguchi T, Matsunoshita Y, Nagao-Kitamoto H, Nagano S, Yokouchi M, Maeda S, Ishidou Y, Yamamoto T, Komiya S.
Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression.
Br. J. Cancer
2015
112:1232-40
PubMed ID: 25742474
DOI: 10.1038/bjc.2015.84
|
|
6426
Igawa K, Xie MF, Ohba H, Yamada S, Hayashi Y.
D-glucosamine conjugation accelerates the labeling efficiency of quantum dots in osteoblastic cells.
Biomed Res Int
2014
2014:821607
PubMed ID: 24818156
DOI: 10.1155/2014/821607
|
|
6427
Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, Kawai A, Morioka H, Toyama Y, Yamada T.
MicroRNA expression and functional profiles of osteosarcoma.
Oncology
2014
86(2):94-103
PubMed ID: 24457375
DOI: 10.1159/000357408
|
|
6428
Arai K, Sakamoto R, Kubota D, Kondo T.
Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.
Proteomics
2013
13(15):2351-60
PubMed ID: 23712969
DOI: 10.1002/pmic.201300053
|
|
6431
Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M, Furukawa K.
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.
Cancer Sci
2012
103(9):1656-64
PubMed ID: 22632091
DOI: 10.1111/j.1349-7006.2012.02344.x
|
|
7968
Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, Nagao H, Komiya S, Setoguchi T.
Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.
PLoS ONE
2011
6:e16234
PubMed ID: 21283769
DOI: 10.1371/journal.pone.0016234
|
|
8031
Iizuka S, Kudo Y, Yoshida M, Tsunematsu T, Yoshiko Y, Uchida T, Ogawa I, Miyauchi M, Takata T.
Ameloblastin regulates osteogenic differentiation by inhibiting Src kinase via cross talk between integrin beta1 and CD63.
Mol. Cell. Biol.
2011
31:783-92
PubMed ID: 21149578
DOI: 10.1128/MCB.00912-10
|
|
18257
Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O, Komiya S.
Smoothened as a new therapeutic target for human osteosarcoma
Mol Cancer
2010
9:5
PubMed ID: 20067614
DOI: 10.1186/1476-4598-9-5
|
|
5180
Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, Komiya S.
The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.
Oncol Rep
2010
23(3):677-84
PubMed ID: 20127006
DOI: 10.3892/or_00000684
|
|
8566
Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K.
Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.
Cancer Sci.
2009
100:1227-33
PubMed ID: 19486338
DOI: 10.1111/j.1349-7006.2009.01165.x
|
|
6435
Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T.
Functional genome screen for therapeutic targets of osteosarcoma.
Cancer Sci
2009
100(12):2268-74
PubMed ID: 19725836
DOI: 10.1111/j.1349-7006.2009.01310.x
|
|
6437
Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F, Naritomi K.
Midkine as a novel target for antibody therapy in osteosarcoma.
Biochem Biophys Res Commun
2007
358(3):757-62
PubMed ID: 17506984
DOI: 10.1016/j.bbrc.2007.04.183
|
|
6438
Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Sugitani M, Nemoto N, Ryu J.
Survivin expression levels as independent predictors of survival for osteosarcoma patients.
J Orthop Res
2007
25(1):116-21
PubMed ID: 17034065
DOI: 10.1002/jor.20291
|
|
6439
Miyazawa K, Kakazu N, Ohyashiki K.
Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Int J Hematol.
2007
85(1):5-10
PubMed ID: 17261495
DOI: 10.1532/IJH97.06047
|
|
3271
Matsunaga T, Yanagiguchi K, Yamada S, Ohara N, Ikeda T, Hayashi Y.
Chitosan monomer promotes tissue regeneration on dental pulp wounds.
J Biomed Mater Res A
2006
76:711-20
PubMed ID: 16315192
DOI: 10.1002/jbm.a.30588
|
|
6440
Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J.
Survivin as a prognostic factor for osteosarcoma patients.
Acta Histochem Cytochem
2006
39(3):95-100
PubMed ID: 17327929
DOI: 10.1267/ahc.06005
|
|
2703
Ohara, Naoko, Hayashi, Yoshihiko, Yamada, Shizuka, Kim, Se-Kwon, Matsunaga, Tsunenori, Yanagiguchi, Kajiro, Ikeda, Takeshi
Early gene expression analyzed by cDNA microarray and RT-PCR in osteoblasts cultured with water-soluble and low molecular chitooligosaccharide.
Biomaterials
2004
25:1749-54
PubMed ID: 14738837
DOI: 10.1016/j.biomaterials.2003.08.022
|
|
2704
Yamada S, Ohara N, Hayashi Y.
Mineralization of matrix vesicles isolated from a human osteosarcoma cell line in culture with water-soluble chitosan-containing medium.
J Biomed Mater Res A
2003
66:500-6
PubMed ID: 12918032
DOI: 10.1002/jbm.a.10009
|
|
6453
Hanaoka E, Ozaki T, Nakamura Y, Moriya H, Nakagawara A, Sakiyama S.
Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells.
Biochem Biophys Res Commun
2000
278(1):20-6
PubMed ID: 11071849
DOI: 10.1006/bbrc.2000.3758
|
Back
Top
CELL BANK Website